Nanobiotix Financial Statements From 2010 to 2024

NANO Stock  EUR 3.50  0.06  1.69%   
Nanobiotix financial statements provide useful quarterly and yearly information to potential Nanobiotix SA investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Nanobiotix financial statements helps investors assess Nanobiotix's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Nanobiotix's valuation are summarized below:
Nanobiotix SA does not presently have any fundamental ratios for analysis.
Check Nanobiotix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nanobiotix's main balance sheet or income statement drivers, such as , as well as many indicators such as . Nanobiotix financial statements analysis is a perfect complement when working with Nanobiotix Valuation or Volatility modules.
  
This module can also supplement various Nanobiotix Technical models . Check out the analysis of Nanobiotix Correlation against competitors.
For information on how to trade Nanobiotix Stock refer to our How to Trade Nanobiotix Stock guide.

Nanobiotix SA Company Return On Equity Analysis

Nanobiotix's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Nanobiotix Return On Equity

    
  -1.99  
Most of Nanobiotix's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nanobiotix SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Nanobiotix SA has a Return On Equity of -1.9869. This is 91.71% lower than that of the Healthcare sector and 192.41% lower than that of the Drug Manufacturers - Major industry. The return on equity for all France stocks is notably higher than that of the company.

Nanobiotix SA Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Nanobiotix's current stock value. Our valuation model uses many indicators to compare Nanobiotix value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nanobiotix competition to find correlations between indicators driving Nanobiotix's intrinsic value. More Info.
Nanobiotix SA is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Nanobiotix by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nanobiotix's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

About Nanobiotix Financial Statements

Nanobiotix stakeholders use historical fundamental indicators, such as Nanobiotix's revenue or net income, to determine how well the company is positioned to perform in the future. Although Nanobiotix investors may analyze each financial statement separately, they are all interrelated. For example, changes in Nanobiotix's assets and liabilities are reflected in the revenues and expenses on Nanobiotix's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Nanobiotix SA. Please read more on our technical analysis and fundamental analysis pages.
Nanobiotix SA, a late stage clinical company, develops and sells nanomedicine for the treatment of cancer worldwide. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France. NANOBIOTIX operates under Drug Manufacturers - Major classification in France and is traded on Paris Stock Exchange. It employs 102 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Nanobiotix Stock

Nanobiotix financial ratios help investors to determine whether Nanobiotix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nanobiotix with respect to the benefits of owning Nanobiotix security.